Systemic treatment for unresectable hepatocellular carcinoma
作者机构：Department of Clinical Tropical MedicineFaculty of Tropical MedicineMahidol UniversityBangkok 10400Thailand Department of MedicineFaculty of MedicineSrinakharinwirot UniversityBangkok 10110Thailand
出 版 物：《World Journal of Gastroenterology》 (世界胃肠病学杂志（英文版）)
年 卷 期：2023年第29卷第10期
页 面：1551-1568页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Hepatocellular carcinoma Unresectable hepatocellular carcinoma Nonalcoholic fatty liver disease Tyrosine kinase inhibitor Sorafenib Lenvatinib Immune checkpoint inhibitor Atezolizumab Bevacizumab
摘 要：Hepatocellular carcinoma(HCC)is most commonly found in the context of liver cirrhosis and,in rare cases,in a healthy *** prevalence has risen in recent years,particularly in Western nations,due to the increasing frequency of nonalcoholic fatty liver *** HCC has a poor *** many years,the only proven therapy for unresectable HCC(uHCC)was sorafenib,a tyrosine kinase ***,the synergistic effect of an immune checkpoint inhibitor,atezolizumab,and bevacizumab outperformed sorafenib alone in terms of survival,making it the recommended first-line *** multikinase inhibitors,lenvatinib and regorafenib,were also recommended as first and second-line drugs,***-stage HCC patients with retained liver function,particularly uHCC without extrahepatic metastasis,may benefit from trans-arterial *** current problem in uHCC is selecting a patient for the best treatment while considering the preexisting liver condition and liver ***,all study patients had a Child-Pugh class A,and the best therapy for other individuals is ***,in the absence of a medical contraindication,atezolizumab could be combined with bevacizumab for uHCC systemic *** studies are now underway to evaluate immune checkpoint inhibitors in combination with anti-angiogenic drugs,and the first findings are *** paradigm of uHCC therapy is changing dramatically,and many obstacles remain for optimum patient management in the near *** purpose of this commentary review was to give an insight into current systemic treatment options for patients with uHCC who are not candidates for surgery to cure the disease.
维普期刊数据库